PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29102694-0	2018	KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma.	Crizotinib	75-85	kinesin family member 5B	Homo sapiens	0-5	
35434049-0	2022	Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report.	Crizotinib	22-32	kinesin family member 5B	Homo sapiens	47-52	
35434049-9	2022	CONCLUSION: Crizotinib sensitivity was observed in an advanced poorly differentiated NSCLC patient with concurrent MET fusions KIF5B-MET and MET-CDR2.	Crizotinib	12-22	kinesin family member 5B	Homo sapiens	127-132	
33832282-7	2021	As far as we know, this is the first report showing that KIF5B-ALK (K20:A20) is a fusion variant that is sensitive to crizotinib.	Crizotinib	118-128	kinesin family member 5B	Homo sapiens	57-62	
33832282-8	2021	We provided a treatment strategy for managing NSCLC patients with KIF5B-ALK (K20:A20) fusion or ALK L1196M mutation after crizotinib resistance.	Crizotinib	122-132	kinesin family member 5B	Homo sapiens	66-71